Format

Send to

Choose Destination
Gynecol Oncol. 2019 Dec;155(3):473-482. doi: 10.1016/j.ygyno.2019.10.004. Epub 2019 Nov 6.

Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.

Author information

1
Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
2
Foundation Medicine, Inc, Cambridge, MA, USA.
3
The Clearity Foundation, San Diego, CA, USA. Electronic address: dzajchowski@clearityfoundation.org.

Abstract

OBJECTIVE:

We analyzed comprehensive genomic sequencing results from paired ovarian cancer samples to identify changes in mutational events over time.

METHODS:

DNA from paired FFPE tumor samples from 50 ovarian cancer patients in the Clearity Foundation Data Repository was analyzed for genomic mutations (GM), copy number alterations (CNA), microsatellite status (MS), tumor mutation burden (TMB), and loss of heterozygosity (LOH) by hybrid-capture, next-generation sequencing of up to 315 genes. Genomic profiles were compared between samples from the same patient. Poor quality results excluded 6 pairs from all analyses and 9 from CNA or LOH.

RESULTS:

Forty-four patients with predominantly advanced stage disease (34, 77%) and serous histology (31, 70%) received a median of 3 intervening treatment regimens (range 1-13). Analysis of 22 primary and recurrent sample pairs and 22 recurrent tumor pairs detected a median of 2 GM (range 0-5) and 1 CNA (range 0-6)/sample. TMB, MS, and LOH results were mostly concordant across paired samples. GM were consistent across most pairs [32/44 (73%) concordant], while CNA concordance was less [18/35 (51%)]. No changes were detected in therapeutically relevant GM, but 23% of patients had GM or CNA in the second sample that affect clinical trial eligibility.

CONCLUSIONS:

Paired ovarian cancer samples demonstrate stable genomic alterations across time. However, discordance was observed for some genes used as eligibility criteria for molecularly targeted clinical trials. Repeat tumor testing may be useful in cases where eligibility for such trials is deemed important after consideration of testing costs and potential clinical benefit.

KEYWORDS:

Copy number alterations; Mutation; Next generation sequencing; Ovarian cancer; Precision medicine; Recurrence

PMID:
31703812
DOI:
10.1016/j.ygyno.2019.10.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center